Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -13.61 | 11.79 | 13.65 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -86.57 | 0.08 | 0.57 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 30.63 | 9.74 | 7.46 | |
| Cash | -16.20 | 6.27 | 7.48 | |
| Capex | 10.99 | -0.01 | -0.02 | |
| Free Cash Flow | -6.18 | -0.77 | -0.73 | |
| Revenue | inf | 0.00 | -2.21 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 1.01 | |
| Operating Margin | inf | 0.00 | 0.43 | |
| ROA | 37.81 | -0.06 | -0.10 | |
| ROE | 39.64 | -0.07 | -0.12 | |
| ROIC | 28.27 | -0.09 | -0.12 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of DNLI is permitted for members.
5
Growth
The "Growth Entry" for the Focus of DNLI is permitted for members.
6
Leverage & Liquidity